Evidence map›Paper›PMID 38158241›Full record

ReviewHematology/oncology clinics of North America2024

Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.

S Vincent Rajkumar, P Leif Bergsagel, Shaji Kumar

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hematology/oncology clinics of North America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

S Vincent RajkumarDivision of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA. Electronic address: rajkumar.vincent@mayo.edu.
P Leif BergsagelDivision of Hematology Oncology, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA.
Shaji KumarDivision of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA.
Mayo Clinic · USMayo Clinic in Arizona · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2M
NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA168762
6 · The paper itself

Abstract

Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 years, or enrollment in clinical trials.

Indexed as

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaSmoldering Multiple MyelomaDisease ProgressionHumansLenalidomideRisk FactorsLenalidomideMyelomaPrognosisSmoldering myelomaTherapy

Identifiers

PMID38158241
PMCPMC11404782
OpenAlexW4390350610

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.